BioFIT: innovation and investors
For two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Uncommon mutations affect breast cancer prognosis
/in News/by Thomas GabrielczykUncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
Argenx in US$1.6bn deal with J&J affiliate Janssen
/in News/by Thomas GabrielczykJanssen affiliate Cilag GmbH International has licenced argenx anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Driver of GVHD after blood stem cell transplantation identified
/in News/by Thomas GabrielczykSwiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.
Investors pool 27m for new Proteomics tech
/in News/by Thomas GabrielczykUK-based biotech startup Fluidic Analytics has raised 27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus […]
Carbios set to build closed-loop PET plant
/in News/by Thomas GabrielczykFrench Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation […]
Adrenomed bags 24m in growth financing
/in News/by Thomas GabrielczykGerman Adrenomed AG has bagged 24m in equity financing from HBM Healthcare Investments and Wellington Partners.
Roche targets asthma with inhalable JAK1 blocker
/in News/by Thomas GabrielczykResearchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
British F2G Biotech bags 24m
/in News/by Thomas GabrielczykThe European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd 24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Sugar replacement slows cancer growth
/in News/by Thomas GabrielczykResearchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.